Active — September 28, 2026 receipt date due at 5:00 PM local time; recurring due dates continue through January 28, 2028Atlas Opportunity Score 96/100
PAR-25-383
NIH Blueprint MedTech Translator (PAR-25-383)
Open NIH Blueprint MedTech UG3/UH3 opportunity for milestone-driven translation and clinical development of novel FDA-regulated medical devices. The next deadline is September 28, 2026 at 5:00 PM local time of the applicant organization. Atlas rates the Nonagon N9+ fit as exceptionally high but conditional on verified device maturity, FDA pathway, disease-specific intended use, evidence, IP, and research-team readiness.
FundingApplication budgets are not limited but must reflect the actual needs of the proposed project. NIH pays approved Blueprint MedTech contractors and consultants directly, so those service costs are not included in the applicant budget.
DeadlineSeptember 28, 2026 at 5:00 PM local time of the applicant organization. Recurring receipt dates continue through January 28, 2028.
Last verifiedSeptember 28, 2026
Required next actionConfirm NIH institute mission fit, device-program entry criteria, required registrations, milestone plans, attachments, and submission readiness for the September 28, 2026 receipt date; the next listed receipt date is January 28, 2027.
Broad Eligibility
Small businesses and other for-profit organizations are eligible, as are multiple higher-education, nonprofit, government, Tribal, and other organization types. Projects must involve novel FDA-regulated device technology within a participating NIH mission and satisfy the program's translational maturity and clinical-study requirements. SAM/UEI, Grants.gov, eRA Commons, and PD/PI eRA Commons registration requirements apply.
Atlas Analysis
This is a milestone-driven NIH cooperative agreement for translational medical-technology development. Applicant readiness depends on program scope, project maturity, supporting evidence, milestone planning, required attachments, registrations, and participating-institute fit.
NIH is accepting applications under PAR-25-383, Blueprint MedTech Translator (UG3/UH3 Clinical Trial Optional) to advance novel medical devices that prevent, monitor, diagnose, or treat disorders within participating NIH institute and initiative missions.
Next deadline: September 28, 2026 at 5:00 PM local time of the applicant organization. Additional receipt dates continue through January 28, 2028. Application budgets are not capped but must reflect actual project needs. The combined UG3 and UH3 project period may not exceed five years, and cost sharing is not required.
Program scope: The UG3 phase supports milestone-driven translational device activities such as prototype implementation, nonclinical testing, design verification and validation, regulatory work, and preparation for an IDE or IRB-approved study. The UH3 phase supports a clinical study. Projects must involve FDA-regulated device technology and generally enter with a device close to the final system, relevant FDA pre-submission feedback, or a need for early-feasibility clinical data. NIH may restrict funding to $100,000 in direct costs until adequate FDA feedback is obtained when the regulatory path has not been sufficiently established.
Atlas fit: N9+ Fit Score 96/100 and Atlas Opportunity Score 95/100, conditional. This is a strong categorical fit for a direct Dr. Miltie pursuit involving the Nonagon N9+ device and platform only if a disease-specific intended use, device maturity, FDA-regulatory pathway, preliminary evidence, intellectual-property position, qualified PI/team, and required registrations can all be verified. No claim is made here about the N9+ regulatory status or readiness for this specific program.
Small businesses and other for-profit organizations are eligible, along with higher education, nonprofit, government, Tribal, and certain other organization types. This is classified as a TRUE Dr. Miltie direct-opportunity candidate for review. It should not be auto-submitted. A decision to pursue should follow immediate verification of the regulatory and research-readiness gates and discussion with the applicable Blueprint MedTech program staff.
Source verificationOfficial government source · grants.nih.govAtlas last verified this record September 28, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
